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Abstract
High platelet to lymphocyte ratio (PLR) and neutrophil to lymphocyte ratio (NLR) are associated with an increased risk of arterial
thrombosis, but their role in venous thromboembolism (VTE) has not been fully investigated. A case–control study, of 486
patients with VTE, 100 with cerebral vein thrombosis (CVT), and 299 healthy individuals, was carried out to investigate whether
high PLR or NLR values are associated with an increased risk of VTE. Patients with high PLR or NLR did not have an increased risk
of VTE (odds ratio [OR] 0.89, 95% confidence interval [CI]: 0.46-1.76; OR: 0.69, 95% CI: 0.34-1.39, respectively) or CVT (OR:
1.65, 95% CI: 0.68-4.00; OR: 0.39, 95% CI: 0.09-1.72, respectively). Subgroups analysis showed that high PLR values were
associated with the risk of provoked CVT (OR: 2.65, 95% CI: 1.02-6.92), and there was an interaction with thrombophilia
abnormalities (OR: 7.67, 95% CI: 1.67-35.27) in patients with CVT. In conclusion, high PLR and NLR values are not associated with
an overall increased risk of VTE or CVT. High PLR values increase the risk of provoked CVT and interact with thrombophilia
abnormalities in patients with CVT.
Keywords
inflammation, inflammation mediators, deep venous thrombosis, intracranial thrombosis, thrombophilia, platelets
Introduction
Venous thromboembolism (VTE) is a major cause of morbidity
and mortality worldwide.1 The identification of acquired or
inherited risk factors for VTE has the potential to improve the
management of patients and the general health of the popula-
tion, helping to adopt the best preventive strategies in sub-
groups of individuals at particularly high risk.
There is a close link between inflammation and thrombosis2
and growing evidence that platelets and neutrophils play an
important role in the development of VTE.3,4 Platelet to lym-
phocyte ratio (PLR) is considered a novel marker that inte-
grates the information about primary hemostasis and
inflammation pathways and seems to be more informative than
platelet count alone.5 So far, high PLR value has been associ-
ated with poor overall survival in several type of malignan-
cies,6-9 found to be an independent predictor of mortality in
patients with ST-elevated myocardial infarction,10 and consid-
ered a prognostic marker in coronary artery disease, predicting
severe atherosclerosis.11 In addition, the neutrophil to lympho-
cyte ratio (NLR) is an established marker of subclinical
inflammation, and high NLR value has been associated with
the presence and the severity of coronary artery disease,12 sug-
gested as predictor of cardiovascular risk and mortality and
considered a prognostic inflammatory marker in various vas-
cular disorders, including severe atherosclerosis.13
The role of PLR and NLR as risk factors for venous throm-
bosis has been poorly investigated, although both PLR and
NLR indexes were found able to discriminate the risk of 30-
day mortality in patients admitted for pulmonary embolism,14
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only 1 study investigate the association between levels of NLR
and future risk or recurrent VTE, finding no association.15
In light of the recent findings on the association between
some alterations of whole blood count, such as red cell distri-
bution width16,17 and an increased risk of VTE, in this case–
control study of exploratory nature, we aimed to investigate
whether high PLR or NLR values, defined as exceeding the
95th percentile of the distribution among controls, were asso-
ciated with an increased risk of VTE (deep vein thrombosis of
the lower limbs and/or pulmonary embolism) or cerebral vein
thrombosis (CVT).
Potential interactions between high PLR or NLR values and
thrombophilia abnormalities were also investigated.
Patients and Methods
Study Population
Patients referred to the Angelo Bianchi Bonomi Thrombosis
Center from January 2007 to December 2013 for thrombophilia
screening after a first, symptomatic, objectively confirmed epi-
sode of VTE or CVT were included in the study. Deep vein
thrombosis was diagnosed by compression ultrasound or veno-
graphy; pulmonary embolism by ventilation/perfusion lung
scan, spiral computed tomography (CT) scan, or pulmonary
angiography; and CVT by cerebral CT scan, angio-nuclear
magnetic resonance, or angiography. Venous thromboembo-
lism or CVT episodes were considered provoked if they
occurred in the presence of such transient risk factors as sur-
gery, prolonged immobilization, trauma, pregnancy, puerper-
ium, or oral contraceptive use and unprovoked in their absence.
Patients with overt hematological or systemic neoplasms,
inflammatory, hepatic or autoimmune disease and those with
antiphospholipid antibodies were excluded from the study
because all these conditions may affect platelet or leukocyte
count. Also patients with hemoglobin levels below normal val-
ues (13.5 g/dL for men and 12.5 g/dL for women), who may
consequently have an increased platelet count, were excluded.
Controls were partners or friends of patients referred to the
Thrombosis Center in the same time period of patients for a
thrombophilia work-up, in whom previous episodes of throm-
bosis were excluded by means of a validated questionnaire,18
avoiding potential selection bias. Demographic and clinical
data were collected at the time of the first visit at the Throm-
bosis Center. The study was approved by the Hospital institu-
tional review board, and all patients and controls signed the
informed consent before inclusion in the study.
Laboratory Tests
Blood samples were collected in vacuum tubes with EDTA as
anticoagulant for automated complete blood count. For the
thrombophilia, screening samples were collected into 3.2%
sodium citrate and centrifuged within 15 minutes at 20C for
20 minutes at 2880g. The plasma obtained was aliquoted and
snap-frozen in liquid nitrogen and then stored at 80C until
analysis. Thrombophilia testing included (i) DNA analysis for
the 1691 guanine to adenine substitution in coagulation factor V
gene (factor V Leiden) and for the 20210 guanine to adenine
substitution in the 30-untranslated region of the prothrombin
gene19,20; (ii) functional and immunoassays (when required) for
plasma fibrinogen, antithrombin, protein C and protein S21; (iii)
antiphospholipid antibodies (lupus anticoagulant, anticardioli-
pin, and anti-b2 glycoprotein I immunoglobulin [Ig]G and IgM
antibodies)22; (iv) plasma factor VIII levels23 with high levels
defined when exceeded the 95th percentile of the distribution
among controls; (v) fasting and postmethionine load (3.8 g per
square meter of body surface area) homocysteine levels with
hyperhomocysteinemia defined when exceeded the 95th percen-
tile of the distribution among controls.24
Serum creatinine and C-reactive protein were also mea-
sured. Creatinine clearance was calculated as a measure of
renal function, according to the Cockroft-Gault formula. All
samples were collected at least 3 months after VTE or CVT, in
order to avoid changes in biological parameters related to the
event, and for controls at the time of the visit.
Statistical Analysis
Continuous variables are presented as mean and standard
deviation or median and interquartile range and categorical
variables as count and percentage. Patients with VTE or CVT
were compared to controls for high PLR and NLR values.
Platelet to lymphocyte ratio and NLR medians were compared
between groups with nonparametric Mann-Whitney U test and
P values <.05 were considered statistically significant. The
analyses were based on dichotomous exposures with cutoff
values at the 95th percentile of the PLR and NLR distribution
of controls, and individuals with values below the 95th percen-
tile were used as reference category. The 95th percentile was
chosen arbitrarily as cutoff value for both PLR and NLR. We
estimated that with this prevalence exposure (5%), to detect a
minimum clinically relevant OR of 2.5, with an a error of 0.05
and a power of 80%, 270 VTE cases and 107 CVT (case–
control ratio of 1:3) were needed. The association between PLR
or NLR with VTE or CVT were expressed in terms of odds
ratios (ORs) as a measure of relative risk with corresponding
95% confidence intervals (CIs). Analyses were adjusted for
possible confounders such as sex, age, and body mass index
using a multivariable logistic regression model. Subgroup anal-
yses were performed, stratifying according to the etiology of
VTE or CVT (provoked or unprovoked). Finally, interaction
analysis was performed to calculate the risk of VTE or CVT
associated with the presence of high PLR or NLR values
(above 95th percentile) and thrombophilia abnormalities. All
analyses were performed with the statistical software SPSS
(release 23.0, IBM SPSS Statistics for Windows, IBM Corp,
Armonk, New York).
Results
The initial study cohort included 1159 patients with VTE, 234
patients with CVT, and 655 healthy controls. After exclusion of
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individuals with missing whole blood count, comorbidities, or
low hemoglobin levels, 486 patients with VTE, 100 with CVT,
and 299 controls remained (Figure 1). Demographic and clin-
ical characteristics of patients excluded were similar to those of
patients included in the final analysis and shown in Table 1.
Patients with CVT were younger than those with VTE and
controls and were mainly women, as CVT typically affects
women in reproductive age. As expected, thrombophilia
abnormalities were more frequent in patients than controls.
Platelet, neutrophil, and lymphocyte mean count did not differ
between groups as well as PLR and NLRmedian values, except
for PLR was lower in patients with VTE than controls (P ¼
.024). Single hematological parameters determining PLR or
NLR, such as platelet, lymphocyte, and neutrophil count, did
not influence the risk of VTE or CVT (data not shown).
The risk of VTE or CVT was not increased with PLR >211
or NLR >3.6, corresponding to the 95th percentile of the
distribution of values among controls (Table 2), also after
adjustment for possible confounders. When provoked and
unprovoked events were considered separately, high PLR val-
ues were associated with an increased risk of provoked CVT
(adj. OR: 2.65, 95% CI: 1.02-6.92; Table 3), whereas high NLR
values did not influence neither the risk of provoked nor unpro-
voked VTE or CVT. No association was observed when
patients were divided into those with blood taken within
(patients with 166 VTE and 14 CVT) and after (patients with
320 VTE and 86 CVT) 3 months from thrombosis (data not
shown). Table 4 shows the interaction analysis of high PLR or
NLR values and thrombophilia abnormalities. An interaction
was observed only for high PLR values and thrombophilia in
patients with CVT (adj. OR: 7.67, 95% CI: 1.67-35.27). This
estimate is 30% greater than the expected risk in the absence of
interaction between the 2 variables [(5.36 þ 1.28)1¼5.64].
Discussion
The identification of risk factors for venous thrombosis is
important to optimize therapeutic and preventive measures in
Figure 1. Selection of the study population.
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Table 1. Demographic and Clinical Characteristics of Patients With Venous Thromboembolism, Cerebral Venous Thrombosis, and Controls.
Characteristic
Patients With Venous
Thromboembolism
Patients With Cerebral
Vein Thrombosis Controls
Number 486 100 299
Age, years, mean (SD) 47.9 (16.1) 36.3 (13.4) 42.9 (12.9)
Men/women 261/225 22/88 126/173
BMI, kg/m2 median (IQR) 25.2 (22.7-28.4) 23.6 (20.4-27.6) 23.4 (21.3-26.9)
Smokers, n (%) 36 (7.4) 13 (13) 31 (10.4)
Thrombophilia abnormalities, n (%)
AT, PC, or PS deficiency 30 (6.2) 6 (6) 4 (1.3)
Factor V Leiden 65 (13.4) 9 (9) 12 (4.0)
G20210A prothrombin mutation 71 (14.6) 22 (22) 5 (1.7)
Hyperhomocysteinemia 29/376 (7.7) 18 (18) 19/215 (8.8)
High factor VIII 87 (17.9) 15 (15) 14 (4.7)
Whole blood count, mean (SD)
Hemoglobin, g/dL 14.4 (1.1) 13.9 (1.1) 14.3 (1.2)
MCV, fL 88.2 (4.5) 87.7 (4.7) 87.8 (4.7)
MPV, fL 10.5 (7.1) 10.7 (1.1) 11.0 (0.8)
Platelets, 103/mL 230.0 (55.2) 242.9 (60.9) 243.1 (54.0)
White cells, 103/mL 6.1 (1.6) 6.0 (1.3) 6.3 (1.6)
Lymphocytes, 103/mL 2.0 (0.6) 1.9 (0.5) 2.0 (0.6)
Neutrophils, 103/mL 3.4 (1.1) 3.3 (1.0) 3.6 (1.3)
Platelets to lymphocyte ratio, mean (SD) 124.3 (45.9)a 130.5 (50.1) 130.1 (44.3)
Neutrophil to lymphocyte ratio, mean (SD) 1.8 (0.8) 1.8 (0.8) 1.9 (1.0)
Other variables, mean (SD)
Creatinine clearance, mL/min 103.5 (34.5) 113.5 (33.5) 101.9 (32.3)
C reactive protein, mg/dL 0.29 (0.49) 0.21 (0.26) 0.21 (0.25)
Fibrinogen, mg/dL 301.2 (58.9) 292.7 (60.7) 284.7 (53.0)
Abbreviations: AT, antithrombin; BMI, body mass index; IQR, interquartile range; MCV, mean corpuscular volume; MPV, mean platelet volume; PC, protein C; PS,
protein S; SD, standard deviation.
aP ¼ .024.
Table 2. Risk of Venous Thromboembolism or Cerebral Vein Thrombosis for Strata of Platelet to Lymphocyte Ratio and Neutrophil to
Lymphocyte Ratio.a
Characteristic Patients, n (%) Controls, n (%) OR (95% CI) Adjusted ORb (95% CI)
PLR
VTE 486 299
95th percentile 464 (95) 284 (95) Ref Ref
>95th percentile 22 (5) 15 (5) 0.89 (0.46-1.76) 0.98 (0.49-1.96)
CVT 100 299
95th percentile 92 (92) 284 (95) Ref Ref
>95th percentile 8 (8) 15 (5) 1.65 (0.68-4.00) 1.48 (0.58-3.76)
NLR
VTE 486 299
95th percentile 469 (96.5) 284 (95) Ref Ref
>95th percentile 17 (3.5) 15 (5) 0.69 (0.34-1.39) 0.71 (0.34-1.48)
CVT 100 299
95th percentile 98 (98) 284 (95) Ref Ref
>95th percentile 2 (2) 15 (15) 0.39 (0.09-1.72) 0.38 (0.08-1.73)
Abbreviations: OR, odds ratio; CI, confidence interval; VTE, venous thromboembolism; CVT, cerebral vein thrombosis; PLR, platelet to lymphocyte ratio; NLR,
neutrophil to lymphocyte ratio; Ref, reference category.
aThe 95th percentile of the distribution of PLR and NLR values among controls were 211 and 3.6, respectively.
bAdjusted for age, sex, and body mass index.
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individuals at risk. Platelet to lymphocyte ratio and NLR are
simple laboratory parameters easily obtained with the whole
blood count and have the advantage to pool information about
primary hemostasis and inflammation. Their prognostic value
has been widely investigated in coronary artery10,11 and cardi-
ovascular12,13 diseases To our knowledge, this is the first study
aiming to investigate PLR and NLR as risk factors for VTE or
CVT. The main finding is the lack of association between high
values of PLR and NLR and an increased risk of venous throm-
bosis. The large sample allowed us to stratify the analysis for
the presence or absence of transient risk factors for thrombosis,
and a 3-fold increased risk of provoked CVT was found for
high PLR values. Finally, an interaction between high PLR
values and the presence of at least 1 marker of thrombophilia
on the risk of CVT was observed.
In the past few years, several studies investigated the
sequence of events linking inflammation to venous thrombo-
sis.4,25,26 An in vivo study identified a cross talk between
monocytes, neutrophils, and platelets; neutrophils provide the
initiating stimuli necessary for thrombus formation and plate-
lets contribute to the propagation of venous thrombus.27 A
recent study in mouse model showed that platelets, neutrophils,
and coagulation factor XII play a role in the pathophysiology of
venous thrombosis.3 Other than composing the majority of the
arterial thrombus, aggregates of platelets are located in the core
of the venous thrombus.28 Indeed, a high platelet count is
Table 3. Risk of Provoked or Unprovoked Venous Thromboembolism or Cerebral Vein Thrombosis for Platelet to Lymphocyte Ratio Above
the 95th Percentile.a
Characteristic Patients, n (%) Controls, n (%) OR (95% CI) Adjusted ORb (95% CI)
PLR >95th percentile
VTE
Provoked (n ¼ 259) 11 (4.2) 15 (5) 0.84 (0.38 -1.86) 0.91 (0.40-2.03)
Unprovoked (n ¼ 227) 11 (4.8) 15 (5) 0.96 (0.43-2.14) 0.95 (0.39-2.33)
CVT
Provoked (n ¼ 69) 8 (11.6) 15 (5) 2.48 (1.01-6.12) 2.65 (1.02-6.92)
Unprovoked (n ¼ 31) – 15 (5) – –
Abbreviations: CI, confidence interval; CVT, cerebral vein thrombosis; OR, odds ratio; PLR, platelet to lymphocyte ratio; VTE, venous thromboembolism.
aThe 95th percentile of the distribution of PLR and NLR values among controls were 211 and 3.6, respectively.
bAdjusted for age, sex, and body mass index.
Table 4. Interaction Between High Platelet to Lymphocyte Ratio and Neutrophil to Lymphocyte Ratio >95th Percentile and Thrombophilia
Abnormalities on The Risk of Venous Thromboembolism or Cerebral Vein Thrombosis.a
PLR >95th/Thrombophilia Patients, n (%) Controls, n (%) OR (95% CI) Adjusted ORb (95% CI)
VTE
/ 244 (50.2) 235 (78.6) Ref Ref
/þ 220 (45.3) 49 (16.4) 4.32 (3.02-6.18) 3.98 (2.77-5.72)
þ/ 13 (2.7) 12 (4) 1.04 (0.47-2.33) 1.15 (0.50-2.61)
þ/þ 9 (1.9) 3 (1) 2.89 (0.77-10.8) 2.74 (0.72-10.40)
CVT
/ 42 (42) 229 (76.6) Ref Ref
/þ 50 (50) 55 (18.4) 4.96 (2.99-8.21) 5.36 (3.13-9.79)
þ/ 3 (3) 12 (4) 1.36 (0.37-5.04) 1.28 (0.33-5.02)
þ/þ 5 (5) 3 (1) 9.09 (2.09-39.47) 7.67 (1.67-35.27)
NLR >95th/Thrombophilia Patients, n (%) Controls, n (%) OR (95% CI) Adjusted ORb (95% CI)
VTE
/ 245 (50.4) 236 (78.9) Ref Ref
/þ 224 (46.1) 48 (16.1) 4.50 (3.14-6.44) 4.11 (2.85-5.91)
þ/ 12 (2.5) 11 (3.7) 1.05 (0.46-2.43) 1.05 (0.46-2.47)
þ/þ 5 (1) 4 (1.3) 1.20 (0.32-4.54) 1.22 (0.32-4.68)
CVT
/ 43 (43) 231 (77.3) Ref Ref
/þ 55 (55) 53 (17.7) 5.58 (3.38-9.18) 6.11 (3.58-10.43)
þ/ 2 (2) 10 (3.3) 1.07 (0.23-5.08) 1.18 (0.24-5.89)
þ/þ - 5 (1.7) - -
Abbreviations: CI, confidence interval; CVT, cerebral vein thrombosis; NLR, neutrophil to lymphocyte ratio; OR, odds ratio; PLR, platelet to lymphocyte ratio;
Ref, reference category; VTE, venous thromboembolism.
aThe 95th percentile of the distribution of PLR and NLR values among controls was 211 and 3.6, respectively.
bAdjusted for age, sex, and body mass index.
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strongly associated with an increased risk of VTE5,29 and, in
response to prohemostatic stimuli, platelets generate circulat-
ing microparticles that are an independent risk factor for
VTE.30 Concerning neutrophils, they get entrapped in the
growing thrombus and, through the extrusion of neutrophils
extracellular traps , are able to recruit other cells that are active
in the coagulation cascade, especially in venous valves where
the flow is minimal.25 Neutrophilia, when persistent over a
3-year period, has been associated with an increased risk of
VTE in patients with such comorbidities as heart, liver, or renal
diseases.31 In addition, leukocytosis influences the thrombotic
risk in patients with myeloproliferative neoplasms,32 and high
PLR and NLR values enhance the risk of cancer-related
VTE.29,33,34 Despite the growing evidence supporting the
hypothesis of the role of platelets, leucocytes, and neutrophils
in thrombus formation, we were not able to demonstrate an
association between high PLR or NLR values and the risk of
VTE or CVT. The 3-fold increased risk of CVT for high PLR
but not NLR values is consistent with other studies in patients
with VTE33 or prosthetic valves thrombosis.35
Some limitations of this study need to be addressed. First,
about one-third of patients with VTE or CVT and half controls
were excluded from the analysis because the information on
blood count was missing. This could have reduced the power of
the study, but not the main conclusion on the lack of association
between high PLR or NLR values and venous thrombosis, since
missing data were random and increasing sample size would
have only improved the precision, but not the size of the risk
estimate. Second, although this is a large sample of CVT
patients from a single Center, it remains relatively small
because of the rarity of the disease. Hence, a weak effect of
high PLR and NLR values on the risk of VTE cannot be
excluded, and further data possibly stemming from prospective
studies are warranted. Third, whether high PLR or NLR values
are causally related to thrombosis in particular subgroups of
patients or are a mere epiphenomenon of the acute phase is still
to be elucidated. It can be speculated that in the presence of
other major risk factors in brain vessels, activated platelets
might enhance the thrombotic risk, especially in the presence
of thrombophilia abnormalities. Moreover, the PLR and NLR
values assessed 3 months after the thrombotic event could have
led to an underestimation of the association, but the lack of
association between thrombosis and PLR and NLR values mea-
sured in the acute phase (ie, within 3 months from the event)
makes unlikely a possible causal relationship, although the
number of patients in the subgroup analysis was further
reduced, particularly for CVT. Finally, being our Thrombosis
Center, a tertiary care center where patients are referred for
thrombophilia work-up, our population might not be represen-
tative of the general population of patients with VTE or CVT
nor can be generalized to arterial thrombosis. In conclusion,
our study may not support high PLR and NLR values as risk
factors for VTE. Whether high PLR values have a role in
provoked CVT, particularly in patients with thrombophilia
abnormalities, remains to be confirmed by further observations,
considering the exploratory nature of this study.
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